Business
Neural Announces Approval of the Strategic Investment and Option Agreement by CWE Shareholders to Acquire up to 100% of CWE
Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany's leading CBD retailers, are pleased to announce that all matters presented to shareholders of CWE, were approved at the special meeting of CWE share
About this update from Neural Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":1,"height":1,"url":"https://www.newsfilecorp.com/newsinfo/259548/202"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D6gQIt2nLjYLP8dh59wlIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2O2g9MzY7Y2Y9d2VicA--/https://www.newsfilecorp.com/newsinfo/259548/202","width":1,"height":1}},"lazy":false},{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of the Germany's leading CBD retailers, are pleased to announce that all matters presented to shareholders of CWE, were approved at the special meeting of CWE shareholders ("CWE Meeting") held on July 17, 2025.","length":595,"tagName":"p"},{"type":"text","content":"The approved resolutions include the Strategic Investment and Option Agreement (the "SIO Agreement") dated May 28, 2025, between Neural and CWE, under which Neural has been granted a two-part investment option to acquire up to 100% of the issued and outstanding shares of CWE through a series of statutory amalgamations under the Business Corporations Act (Ontario). The resolutions also included approval of various ancillary transactions (the "CWE Reorganization") required to be implemented by CWE in order to facilitate the transactions contemplated under the SIO Agreement.","length":598,"tagName":"p"},{"type":"text","content":"The CWE Reorganization includes a series of internal steps, such as the exchange of common shares in the capital of CWE ("CWE Shares") for shares of three newly incorporated CWE subsidiaries (CWE NewCo A, B, and C), followed by one or more three-cornered amalgamations between those entities and subsidiaries of Neural, subject to securing the requisite approvals.","length":374,"tagName":"p"},{"type":"text","content":"These internal steps are designed to facilitate Neural's option-based acquisition of CWE in discrete phases—starting with the potential exercise of the Series A Option—and to support operational and tax ef...